The Impact of Treatment Resistance in Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 10 December 2025 | Viewed by 87
Special Issue Editor
Special Issue Information
Dear Colleagues,
The past decade of genomic profiling has proven that prostate cancer (PCa) is a heterogeneous disease, and the cellular and extracellular factors responsible for prostate cancer progression and therapeutic resistance remain unclear. Primary PCa is driven by activation of the androgen receptor (AR), and most patients initially respond well to androgen deprivation therapy (ADT). However, almost all patients will progress to castration-resistant prostate cancer (CRCP), which has no effective treatments. The therapeutic landscape for prostate cancer has dramatically changed due to advances in ADT, radiation, and the introduction of immunotherapy. While these treatments have shown success and improved patient outcomes, they are not curative and select for more aggressive, highly resistant forms of prostate cancer. Therefore, there is a need for a complete understanding of the cellular and tumor microenvironmental factors that facilitate therapeutic resistance, not just the androgen receptor (AR)’s signaling cascade, to identify new drug targets. The objective of this collection is to highlight the latest insights into PCa progression, the mechanisms of drug resistance, and new approaches to targeted therapy.
Dr. Noel Andrew Warfel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- treatment resistance
- progression
- drug target
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
